Clinical 1-year post-surgical data results show significant patient improvement
The data is from 10 European orthopaedic sites and is presented in the scientific abstract "Short-term clinical results of a customized metal mini-prosthesis for focal chondral lesions", Magnus Högström1, Peter Verdonk2, Semin Becirbegovic3, Geir Hilstöl4, Johannes Holz5, Tobias Jung6, Lars Konradsen7, Jens-Ole Laursen8, Martin Lind9, Tim Spalding10.
Sports Medicine Umeå, Sweden1, Antwerp Orthopedic Center, Belgium2, University Clinical Center Sarajevo, Bosnia Herzegovina3, Drammen Hospital, Norway4, OrthoCentrum Hamburg, Germany5, Charité Universitätsmedizin Berlin, Germany6, Bispebjerg Hospital, Denmark7, Sygeshus Sonderjylland, Denmark8, Aarhus University Hospital, Denmark9, University Hospitals Coventry and Warwickshire NHS Trust, UK10.
The scientific abstract will be presented by the main author, Magnus Högström, MD PhD, at the SFAIM-meeting (Swedish Association for Physical Activity and Sports Medicine), May 20, 2016.
The compiled clinical results presented in the scientific abstract show that VAS data ”Visual Analogue Scale" (100 = most pain, 0 = no pain) has improved from 60 pre-surgery to 27 at 12 months time-point. The corresponding aggregated KOOS data ”Knee injury and Osteoarthritis Outcome Score” (100 = no knee problems, 0 = severe knee problems) has improved from 39 pre-surgery to 67 at 12 months time-point.
“Our data shows great results after 1-year follow-up. The experience until now is very good. My patients show an almost normalized knee function after the procedure. Post-surgery patients experience pain relief and improved knee function and the rehabilitation has been smooth and easy. The Episealer implant has an advanced design but the surgery itself is quick and easy. This novel Swedish knee implant provides new treatment options for patients with cartilage lesions, especially for middle-aged patients where we have been lacking efficient treatment options. The Episealer enables a good knee function for these patients.‘’ says Dr Högström.
"It is very satisfying that we can now report clinical data showing that patients are truly helped by the Episealer implant, most patients having almost normal knees. Especially so since these first cases were often salvage procedures with patients having been operated on previously and failed. It is also reassuring that these results do not seem to deteriorate with time. Finally, we can also, after 3.5 years of implantation, appreciate that there have been no revisions at all” comments Dr Leif Ryd, Senior Medical Advisor and Board Member, Episurf Medical.
"These clinical results are important and exciting. This compelling evidence demonstrates the value of our patient specific approach with the pre-surgical damage marking report, intelligent implant design and bespoke guide instrumentation. I am confident that the growing evidence base of scientific results will further increase surgical adoption of Episealer in clinical practice,“ says Rosemary Cunningham Thomas, CEO of Episurf Medical.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
rosemary@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.